NPF Seal of Recognition Awarded to Ilumya® for Ease of Use
ALEXANDRIA, VA, UNITED STATES, August 6, 2026 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) is pleased to announce that Sun Pharma’s Ilumya® has earned the NPF Seal of Recognition for its ease of usability and safety. This is the first systemic prescription medication to earn the Seal.
Unlike self-administered injectable therapies, Ilumya® is administered by a healthcare professional in a clinical setting, eliminating the need for patients to prepare or self-inject their medication. For many people living with psoriasis, self-injection can present a significant physical challenge and may contribute to treatment burden.
By removing the physical demands of self-administration, Ilumya® supports a more accessible treatment experience. This patient-centered approach aligns with the National Psoriasis Foundation's Seal of Recognition criteria, which recognize products that help reduce barriers and support the unique needs of people living with psoriasis.
Products earn the NPF Seal of Recognition by submitting independent lab data to a panel of experts who review for safety. Companies and products that earn the NPF Seal of Recognition have demonstrated a commitment to creating safe products for the more than 8 million people in the U.S. and 125 million people worldwide who are impacted by psoriasis.
“We are pleased to have Sun Pharma’s Ilumya® earn our coveted NPF Seal of Recognition. It shows their dedication to best serving our community,” says Leah M. Howard, J.D., the President and CEO of NPF. “The ease of usability and the safety offered by healthcare professional administered dosing can help many adults with plaque psoriasis feel at ease in receiving their treatment.”
Ilumya® (tildrakizumab-asmn) has been indicated by the U.S. Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis that are candidates for systemic treatments or phototherapy. [1]
About the National Psoriasis Foundation
The National Psoriasis Foundation is the leading nonprofit representing individuals with psoriasis and psoriatic arthritis. The mission of NPF is to drive efforts to cure psoriatic disease and improve the lives of more than 8 million individuals in the United States affected by this chronic immune-mediated disease. Learn more at psoriasis.org.
About the NPF Seal of Recognition
The NPF Seal of Recognition highlights and recognizes products created or intended to be non-irritating and safe for those living with psoriasis or psoriatic arthritis. The directory also recognizes products that are safe as part of a daily skincare routine for sensitive skin or suitable for those with joint mobility limitations.
REFERENCES
[1] Efficacy Results | ILUMYA® (tildrakizumab-asmn)
Unlike self-administered injectable therapies, Ilumya® is administered by a healthcare professional in a clinical setting, eliminating the need for patients to prepare or self-inject their medication. For many people living with psoriasis, self-injection can present a significant physical challenge and may contribute to treatment burden.
By removing the physical demands of self-administration, Ilumya® supports a more accessible treatment experience. This patient-centered approach aligns with the National Psoriasis Foundation's Seal of Recognition criteria, which recognize products that help reduce barriers and support the unique needs of people living with psoriasis.
Products earn the NPF Seal of Recognition by submitting independent lab data to a panel of experts who review for safety. Companies and products that earn the NPF Seal of Recognition have demonstrated a commitment to creating safe products for the more than 8 million people in the U.S. and 125 million people worldwide who are impacted by psoriasis.
“We are pleased to have Sun Pharma’s Ilumya® earn our coveted NPF Seal of Recognition. It shows their dedication to best serving our community,” says Leah M. Howard, J.D., the President and CEO of NPF. “The ease of usability and the safety offered by healthcare professional administered dosing can help many adults with plaque psoriasis feel at ease in receiving their treatment.”
Ilumya® (tildrakizumab-asmn) has been indicated by the U.S. Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis that are candidates for systemic treatments or phototherapy. [1]
About the National Psoriasis Foundation
The National Psoriasis Foundation is the leading nonprofit representing individuals with psoriasis and psoriatic arthritis. The mission of NPF is to drive efforts to cure psoriatic disease and improve the lives of more than 8 million individuals in the United States affected by this chronic immune-mediated disease. Learn more at psoriasis.org.
About the NPF Seal of Recognition
The NPF Seal of Recognition highlights and recognizes products created or intended to be non-irritating and safe for those living with psoriasis or psoriatic arthritis. The directory also recognizes products that are safe as part of a daily skincare routine for sensitive skin or suitable for those with joint mobility limitations.
REFERENCES
[1] Efficacy Results | ILUMYA® (tildrakizumab-asmn)
Matt Werbach
National Psoriasis Foundation
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.